Skip to content

NBTX

Nanobiotix SA

NASDAQ · Healthcare · Biotechnology · FR

$33.05
−7.89%
Ask drillr

Year over year

Reported trailing growth

Revenue
+512.3%
EBITDA
+82.0%
EBIT
+84.2%
EPS
+65.3%
Free cash flow
-66.5%
Operating cash flow
-70.9%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+83.8%
EBITDA
+82.2%
EBIT
+84.2%
Net income
+64.8%
EPS
+65.3%
Free cash flow
-66.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025